HomeCLLS • NASDAQ
add
Cellectis SA
Previous close
$2.49
Day range
$2.35 - $2.51
Year range
$0.96 - $3.77
Market cap
183.82M USD
Avg Volume
30.42K
Market news
Financials
Income Statement
Revenue
Net income
(USD) | Sep 2023info | Y/Y change |
---|---|---|
Revenue | 1.64M | -12.51% |
Operating expense | 22.13M | -23.32% |
Net income | -17.48M | 38.59% |
Net profit margin | -1.06K | 29.81% |
Earnings per share | -0.37 | 41.27% |
EBITDA | -18.18M | 26.66% |
Effective tax rate | -0.61% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Sep 2023info | Y/Y change |
---|---|---|
Cash and short-term investments | 67.36M | -43.30% |
Total assets | 209.70M | -24.99% |
Total liabilities | 133.58M | -0.29% |
Total equity | 76.12M | — |
Shares outstanding | 55.58M | — |
Price to book | 1.82 | — |
Return on assets | -23.63% | — |
Return on capital | -30.07% | — |
Cash Flow
Net change in cash
(USD) | Sep 2023info | Y/Y change |
---|---|---|
Net income | -17.48M | 38.59% |
Cash from operations | -17.09M | 34.36% |
Cash from investing | -300.00K | -391.80% |
Cash from financing | 1.69M | 140.97% |
Net change in cash | -17.03M | 46.44% |
Free cash flow | -10.50M | 24.69% |
About
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina. Wikipedia
Founded
1999
Website
Employees
234